Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor

被引:870
|
作者
Sadler, J. E.
Budde, U.
Eikenboom, J. C. J.
Favaloro, E. J.
Hill, F. G. H.
Holmberg, L.
Ingerslev, J.
Lee, C. A.
Lillicrap, D.
Mannucci, M.
Mazurier, C.
Meyer, D.
Nichols, W. L.
Nishino, M.
Peake, I. R.
Rodeghiero, F.
Schneppenheim, R.
Ruggeri, Z. M.
Srivastava, A.
Montgomery, R. R.
Federici, A. B.
机构
[1] Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA
[2] Lab Assoc Prof Arndt & Partners, Hamburg, Germany
[3] Leiden Univ, Med Ctr, Dept Haematol, Leiden, Netherlands
[4] Westmead Hosp, ICPMR, Westmead, NSW 2145, Australia
[5] Birmingham Childrens Hosp NHS Trust, Dept Haematol, Birmingham, W Midlands, England
[6] Univ Lund Hosp, Dept Pediat, S-22185 Lund, Sweden
[7] Univ Hosp Skejby, Dept Clin Immunol, Aarhus, Denmark
[8] Royal Free Hosp, Haemophilia Ctr, London NW3 2QG, England
[9] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada
[10] IRCCS Maggiore Policlin Hosp, Angelo Bianchi Bonomi Hemophilia Thrombosis Ctr, Dept Med Specialties, Milan, Italy
[11] Regina Elena Fdn, Milan, Italy
[12] Univ Milan, Milan, Italy
[13] Lab Srancais Fractionnement & Biotechnol, Lille, France
[14] Hop Bicetre, INSERM, U770, Le Kremlin Bicetre, France
[15] Mayo Clin, Div Hematol & Internal Med, Rochester, MN USA
[16] Nara Prefectural Nara Hosp, Dept Pediat, Nara, Japan
[17] San Bortolo Hosp, Dept Haematol, Hemophilia & Thrombosis Ctr, Vicenza, Italy
[18] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hematol & Oncol, Hamburg, Germany
[19] Scripps Res Inst, Roon Res Lab Arteriosclerosis & Thrombosis, La Jolla, CA USA
[20] Christian Med Coll & Hosp, Dept Hematol, Vellore, Tamil Nadu, India
[21] Blood Res Inst, Milwaukee, WI USA
关键词
ADAMTS-13; classification; pathophysiology; von Willebrand disease;
D O I
10.1111/j.1538-7836.2006.02146.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
von Willebrand disease (VWD) is a bleeding disorder caused by inherited defects in the concentration, structure, or function of von Willebrand factor (VWF). VWD is classified into three primary categories. Type 1 includes partial quantitative deficiency, type 2 includes qualitative defects, and type 3 includes virtually complete deficiency of VWF. VWD type 2 is divided into four secondary categories. Type 2A includes variants with decreased platelet adhesion caused by selective deficiency of high-molecular-weight VWF multimers. Type 2B includes variants with increased affinity for platelet glycoprotein Ib. Type 2M includes variants with markedly defective platelet adhesion despite a relatively normal size distribution of VWF multimers. Type 2N includes variants with markedly decreased affinity for factor VIII. These six categories of VWD correlate with important clinical features and therapeutic requirements. Some VWF gene mutations, alone or in combination, have complex effects and give rise to mixed VWD phenotypes. Certain VWD types, especially type 1 and type 2A, encompass several pathophysiologic mechanisms that sometimes can be distinguished by appropriate laboratory studies. The clinical significance of this heterogeneity is under investigation, which may support further subdivision of VWD type 1 or type 2A in the future.
引用
收藏
页码:2103 / 2114
页数:12
相关论文
共 50 条
  • [31] Von Willebrand Factor Modifiers and their effect on Subjects with and without von Willebrand Disease
    Depka, Mariovon
    Detering, Carsten
    Fursa, Alina
    Martensen, Hauke
    Wermes, Cornelia
    HAEMOPHILIA, 2014, 20 : 115 - 115
  • [32] Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome
    Stufano, Francesca
    Boscarino, Marco
    Bucciarelli, Paolo
    Baronciani, Luciano
    Maino, Alberto
    Cozzi, Giovanna
    Peyvandi, Flora
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2019, 45 (01): : 36 - 42
  • [33] Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease
    Schwarz, HP
    Dorner, F
    Mitterer, A
    Mundt, W
    Schlokat, U
    Pichler, L
    Turecek, PL
    HAEMOPHILIA, 1998, 4 : 53 - 62
  • [34] The Effect of Age on von Willebrand Factor and Bleeding Symptoms in von Willebrand Disease
    Seaman, Craig D.
    Ragni, Margaret, V
    THROMBOSIS AND HAEMOSTASIS, 2020, 120 (08) : 1159 - 1165
  • [35] In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease
    Turecek, PL
    Gritsch, H
    Pichler, L
    Auer, W
    Fischer, B
    Mitterer, A
    Mundt, W
    Schlokat, U
    Dorner, F
    Erinkman, HJM
    vanMourik, JA
    Schwarz, HP
    BLOOD, 1997, 90 (09) : 3555 - 3567
  • [36] Von Willebrand factor inhibitors developed in type 3 von Willebrand disease
    Megdiche, F.
    Kassar, O.
    Hdiji, S.
    Mbarek, L.
    Charfi, M.
    Elloumi, M.
    Kallel, C.
    HAEMOPHILIA, 2019, 25 : 87 - 87
  • [37] Reduced von Willebrand factor survival in type Vicenza von Willebrand disease
    Casonato, A
    Pontara, E
    Sartorello, F
    Cattini, MG
    Sartori, MT
    Padrini, R
    Girolami, A
    BLOOD, 2002, 99 (01) : 180 - 184
  • [38] Four novel von Willebrand factor mutations in mild von Willebrand disease
    Castaman, G.
    Giacomelli, S.
    Coppola, A.
    Rodeghiero, F.
    Tosetto, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 943 - 943
  • [39] Oligosaccharide structures of von Willebrand factor and their potential robe in von Willebrand disease
    Millar, CM
    Brown, SA
    BLOOD REVIEWS, 2006, 20 (02) : 83 - 92
  • [40] Pharmacokinetics of a Recombinant Von Willebrand Factor in Patients with Severe Von Willebrand Disease
    Ragni, Margaret V.
    Castaman, Giancarlo
    Gill, Joan Cox
    Kouides, Peter
    Chapman, Miranda
    Sytkowski, Arthur
    Obermann-Slupetzky, Ortrun
    Presch, Isabella
    Fritsch, Sandor
    Ewenstein, Bruce M.
    BLOOD, 2015, 126 (23)